Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria
Geoffrey D E Cuvelier,Eneida R Nemecek,Justin T Wahlstrom,Carrie L Kitko,Victor A Lewis,Tal Schechter,David A Jacobsohn,Andrew C Harris,Michael A Pulsipher,Henrique Bittencourt,Sung Won Choi,Emi H Caywood,Kimberly A Kasow,Monica Bhatia,Benjamin R Oshrine,Allyson Flower,Sonali Chaudhury,Donald Coulter,Joseph H Chewning,Michael Joyce,Süreyya Savaşan,Anna B Pawlowska,Gail C Megason,David Mitchell,Alexandra C Cheerva,Anita Lawitschka,Lori J West,Bo Pan,Yazid N Al Hamarneh,Anat Halevy,Kirk R Schultz
DOI: https://doi.org/10.1182/blood.2019000216
IF: 20.3
2019-07-18
Blood
Abstract:Chronic graft-versus-host disease (cGVHD) and late acute graft-versus-host disease (L-aGVHD) are understudied complications of allogeneic hematopoietic stem cell transplantation in children. The National Institutes of Health Consensus Criteria (NIH-CC) were designed to improve the diagnostic accuracy of cGVHD and to better classify graft-versus-host disease (GVHD) syndromes but have not been validated in patients <18 years of age. The objectives of this prospective multi-institution study were to determine: (1) whether the NIH-CC could be used to diagnose pediatric cGVHD and whether the criteria operationalize well in a multi-institution study; (2) the frequency of cGVHD and L-aGVHD in children using the NIH-CC; and (3) the clinical features and risk factors for cGVHD and L-aGVHD using the NIH-CC. Twenty-seven transplant centers enrolled 302 patients <18 years of age before conditioning and prospectively followed them for 1 year posttransplant for development of cGVHD. Centers justified their cGVHD diagnosis according to the NIH-CC using central review and a study adjudication committee. A total of 28.2% of reported cGVHD cases was reclassified, usually as L-aGVHD, following study committee review. Similar incidence of cGVHD and L-aGVHD was found (21% and 24.7%, respectively). The most common organs involved with diagnostic or distinctive manifestations of cGVHD in children include the mouth, skin, eyes, and lungs. Importantly, the 2014 NIH-CC for bronchiolitis obliterans syndrome perform poorly in children. Past acute GVHD and peripheral blood grafts are major risk factors for cGVHD and L-aGVHD, with recipients ≥12 years of age being at risk for cGVHD. Applying the NIH-CC in pediatrics is feasible and reliable; however, further refinement of the criteria specifically for children is needed.